CVA Family Office’s Roivant Sciences ROIV Stock Holding History

CVA Family Office’s Portfolio ROIV Stock Details ROIV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$16.7K	Buy	472 +93	+25%	+$2.75K	﹤0.01%	867
2026 Q1	$10.5K	Buy	+379	New	+$9.74K	﹤0.01%	976

Other funds holding ROIV

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

QVT Financial New York $1.7B AUM 173.77% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

CVA Family Office's ROIV Position: Q2 2026 in Review

CVA Family Office increased its Roivant Sciences (ROIV) stake by 25% in Q2 2026, buying an estimated $2.75K and bringing the position to 472 shares worth $16.7K. The position accounts for ﹤0.01% of the portfolio, ranked #867.

CVA Family Office first reported a position in ROIV in Q1 2026 and has held it in 2 quarters since. 498 funds tracked by Wall St. Rank hold ROIV as of Q2 2026.

CVA Family Office held 472 shares of Roivant Sciences worth $16.7K as of Q2 2026.
CVA Family Office bought 93 Roivant Sciences shares in Q2 2026, an estimated $2.75K.
Roivant Sciences made up ﹤0.01% of CVA Family Office's portfolio in Q2 2026, its #867 holding.
CVA Family Office first reported a position in Roivant Sciences in Q1 2026 and has held it in 2 quarters since.
498 funds tracked by Wall St. Rank held Roivant Sciences as of Q2 2026.

Based on CVA Family Office's 13F filing for Q2 2026, filed 7 Aug 2026.